OncoSil Medical

Industry Lists

OncoSil Medical Limited (OSL, NeuroDiscovery Ltd) is an Australia-based and ASX-listed medical device company focused on localised treatments for patients with pancreatic and liver cancer.

OncoSil's lead product, OncoSil, is a first in class medical device with targeted radioactive isotope (Phosphorous-32) implanted directly into a patient's pancreatic tumors via an endoscopic ultrasound. This treatment, known as brachytherapy, is intended to deliver more concentrated and localized radiation.

Contact Details

Suite 402, Level 4, 50 Berry Street, NORTH SYDNEY NSW 2060

02 9223 3344

info@oncosil.com.au

www.oncosil.com

Lists and Charts

Share price

Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 31/10/24

Rank	Company	1 yr	5 yr
1074^th	OncoSil Medical	-15%	-37%

View Full List

1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Revenue

Rank		Company	Revenue
^th		OncoSil Medical	$1.1m

View Full List

1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®

Share Transactions

19/12/23

$366k Issued

Nigel Lange

30/06/23

$64k Sold

Otto Buttula

11/05/23

$10k Issued

Nigel Lange

Total value as at the date of the transaction

Company Activity

	NEW ROLE: Doug Cubbin, Non-Executive Director	07 Aug 2024
	NEW ROLE: Gabriel Liberatore, Non-Executive Director	07 Aug 2024
	NEW ROLE: Brian Leedman, Non-Executive Director	26 Apr 2023
	NEWS: Tagged in Market chemistry grows biotech deals	19 Sep 2022
	NEWS: Tagged in Investors turn to innovation	19 Sep 2022
	NEW ROLE: Otto Buttula, Non-Executive Chair	16 Feb 2022
	NEW ROLE: Ricky Sharma, Non-Executive Director	16 Feb 2022
	NEW ROLE: Nigel Lange, Chief Executive, Managing Director	14 Apr 2021
	REMUNERATION UPDATE: Tom Milicevic, Chief Financial Officer, Company Secretary	03 Nov 2020